Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: Requirement for mTORC1 activity associates with ER-alpha expression

Breast Cancer Research and Treatment

Volumn 135, Issue 2, 2012, Pages 469-479

  Hall, Ben A ^a   Kim, Tae Yeon ^a   Skor, Maxwell N ^a   Conzen, Suzanne D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Breast cancer; Estrogen receptor alpha (ER ); Mammalian target of rapamycin (mTOR); Phosphoinositide 3 kinase (PI3K); Rapamycin; Serum and glucocorticoidregulated kinase 1 (SGK1)

Indexed keywords

DEXAMETHASONE; ESTROGEN RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SERINE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SHORT HAIRPIN RNA; THREONINE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME ACTIVATORS; ESTROGEN RECEPTOR ALPHA; FEMALE; FURANS; HUMANS; IMMEDIATE-EARLY PROTEINS; INSULIN; MCF-7 CELLS; MULTIPROTEIN COMPLEXES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; PYRIDINES; PYRIMIDINES; SIROLIMUS; THAPSIGARGIN; TOR SERINE-THREONINE KINASES;

EID: 84866540757     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2161-y     Document Type: Article

References (36)

1. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22 (Pubitemid 47001784)
2. Jankiewicz M, Groner B, Desrivieres S (2006) Mammalian target of rapamycin regulates the growth of mammary epithelial cells through the inhibitor of deoxyribonucleic acid binding Id1 and their functional differentiation through Id2. Mol Endocrinol 20:2369-2381 (Pubitemid 44496407)
3. Carraway H, Hidalgo M (2004) New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6:219-224
4. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159-168
5. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME (2001) Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 21:952-965 (Pubitemid 32104742)
6. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD (2001) Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, SGK-1. J Biol Chem 276:16649-16654
7. Kobayashi T, Cohen P (1999) Activation of serum-and glucocorticoid- regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem J 339:319-328 (Pubitemid 29209961)
8. Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, Hemmings BA (1999) Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J 18:3024-3033 (Pubitemid 29255611)
9. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM (2008) mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30:701-711 (Pubitemid 351815130)
10. Garcia-Martinez JM, Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416:375-385
11. Chang SB, Miron P, Miron A, Iglehart JD (2007) Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res 138:37-44 (Pubitemid 46227456)
12. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F (2004) Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10:1013-1023 (Pubitemid 38198903)
13. Witton CJ (2005) Determining sensitivity to rapamycin and its analogues in breast cancer patients. Breast Cancer Res 7:41-42 (Pubitemid 40214537)
14. Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM, Gray NS (2010) Discovery of 1-(4-(4-propionylpiperazin-1- yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H) -one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem 53:7146-7155
15. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS (2009) An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032
16. Pew T, Zou M, Brickley DR, Conzen SD (2008) Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator expression via the serum and GC regulated kinase-1/forkhead Box O3a pathway. Endocrinology 149:2637-2645 (Pubitemid 351574483)
17. Belova L, Brickley DR, Ky B, Sharma SK, Conzen SD (2008) Hsp90 regulates the phosphorylation and activity of serum-and glucocorticoid-regulated kinase-1. J Biol Chem 283:18821-18831
18. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101 (Pubitemid 40262113)
19. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112-1116
20. Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F (2009) The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer 8:75
21. Holz MK, Blenis J (2005) Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 280:26089-26093 (Pubitemid 41022201)
22. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM (2006) A pharmacological map of the PI3-K family defines a role for p110[alpha] in insulin signaling. Cell 125:733-747
23. Thastrup O, Dawson AP, Scharff O, Foder B, Cullen PJ, Drobak BK, Bjerrum PJ, Christensen SB, Hanley MR (1989) Thapsigargin, a novel molecular probe for studying intracellular calcium release and storage. Agents Actions 27:17-23 (Pubitemid 19108485)
24. Hu P, Han Z, Couvillon AD, Exton JH (2004) Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J Biol Chem 279:49420-49429 (Pubitemid 39625828)
25. Sherk AB, Frigo DE, Schnackenberg CG, Bray JD, Laping NJ, Trizna W, Hammond M, Patterson JR, Thompson SK, Kazmin D, Norris JD, McDonnell DP (2008) Development of a small-molecule serum-and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res 68:7475-7483
26. Murray JT, Campbell DG, Morrice N, Auld GC, Shpiro N, Marquez R, Peggie M, Bain J, Bloomberg GB, Grahammer F, Lang F, Wulff P, Kuhl D, Cohen P (2004) Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J 384:477-488 (Pubitemid 40018961)
27. Inglis SK, Gallacher M, Brown SG, McTavish N, Getty J, Husband EM, Murray JT, Wilson SM (2009) SGK1 activity in Na? absorbing airway epithelial cells monitored by assaying NDRG1-Thr346/356/366 phosphorylation. Pflugers Arch 457:1287-1301
28. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166:213-223 (Pubitemid 38988774)
29. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK, Lee AV (2001) Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 61:5771-5777 (Pubitemid 32769093)
30. Walker MP, Zhang M, Le TP, Wu P, Laine M, Greene GL (2011) RAC3 is a pro-migratory co-activator of ERalpha. Oncogene 30:1984-1994
31. Baskin R, Sayeski PP (2011) Angiotensin II mediates cell survival through upregulation and activation of the serum and glucocorticoid inducible kinase 1. Cell Signal 24:435-442
32. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK (2009) S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 284: 6361-6369
33. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314-5322 (Pubitemid 46206985)
34. Buckner JC, Forouzesh B, Erlichman C, Hidalgo M, Boni JP, Dukart G, Berkenblit A, Rowinsky EK (2010) Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest New Drugs 28:334-342
35. Baselga J, Campone M, Sahmoud TPM, Burris H, Rugo H, Noguchi S, Gnant MMP (2011) Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: results of the BOLERO-2 phase III trial. J Clin Oncol 29:suppl (abstr e11058)
36. Bachelot T, Bourgier C, Cropet C, Guastalla J-P, Ferrero J-M, Leger-Falandry C, Soulie P, Eymard J-C, Debled M, Spaeth D, Legouffe E, Delozier T, El Kouri CJC (2010) TAMRAD: a GINECO randomized phase II Trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Cancer Res 70:S1-6